enGene Therapeutics Inc. (ENGN): EPS (Basic)

Annual figures by period end, from SEC filings.

$2.29

Year ended 2025-10-31

-62.7%

3-year compound annual growth

2022-10-31 EPS (Basic) (USD per share) 2025-10-31

Period ended	EPS (Basic)	Change YoY	Source filing
2025-10-31	$2.29	+56.8%	2025-12-22, From 2024-11-01
2024-10-31	$1.46	-99.0%	2025-12-22, From 2023-11-01
2023-10-31	$151.22	+241.4%	2024-12-19, From 2022-11-01
2022-10-31	$44.30	n/a	2024-01-29, From 2021-11-01

EPS (Basic) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EPS (Basic)	Change YoY
enGene Therapeutics Inc. (ENGN)	2025-10-31	$2.29	+56.8%
Metagenomi Therapeutics, Inc. (MGX)	2025-12-31	-$2.36	n/m
Compass Therapeutics, Inc. (CMPX)	2025-12-31	-$0.42	n/m
Century Therapeutics, Inc. (IPSC)	2025-12-31	-$0.14	n/m
Agenus Inc (AGEN)	2025-12-31	$0.00	n/m
TScan Therapeutics, Inc. (TCRX)	2025-12-31	-$1.00	n/m
Solid Biosciences Inc. (SLDB)	2025-12-31	-$1.99	n/m
DBV Technologies S.A. (DBVT)	2025-12-31	-$1.05	n/m
Protara Therapeutics, Inc. (TARA)	2025-12-31	-$1.34	n/m

Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗